#United States #Class Action #San Francisco #Gossamer Bio #seralutinib

Gossamer Bio Under Fire Following PROSERA Trial Results

Gossamer Bio, Inc. is facing a class action lawsuit filed on behalf of investors who suffered losses due to undisclosed risks associated with the company's Phase 3 clinical trial results for seralutinib, aimed at treating pulmonary arterial hypertension (PAH). The lawsuit, initiated by Hagens Berman firm, highlights alleged securities law violations by the company, particularly regarding the transparency of its trial design and results.

The class period for the lawsuit spans from June 16, 2025, to February 20, 2026. During this timeframe, Gossamer investors felt optimistic about the potential of seralutinib after management assured them of a promising future for the drug, which was positioned as a potential “first-in-class” treatment. However, following a drastic announcement on February 23, 2026, stating the PROSERA trial did not meet its primary endpoint, the company's shares plummeted by 80%.

This shocking revelation came just months after Gossamer's management had cited confidence in their trial based on comparatives to a successful Merck study. They had emphasized a robust patient recruitment protocol, poised to generate substantial data by attracting participants from regions known for high efficacy outcomes. Yet, unbeknownst to investors, there were significant flaws regarding the trial’s design and execution that may have inflated expectations.

In the aftermath of the trial’s fiasco, investors were led to believe by Gossamer's leaders that improvements seen in the trial were due to the medication's efficacy, rather than a skewed placebo response. Evidence later suggested that many patients in Latin America, involved in the study, had previously undergone extensive treatments prior to participating in the trial, compromising the trial's validity. The company concealed these critical issues from its stakeholders.

Leading legal representatives from the Hagens Berman firm emphasized their commitment to uncovering the truth behind Gossamer’s disclosures and any potential misguidance towards investors. The lawsuit presents a stark reminder of the importance of transparency and honesty from companies involved in clinical trials, particularly when investors’ trust and finances are at stake.

“Investors deserve to know the truth about their investments,” said Reed Kathrein, a partner at Hagens Berman. “Our investigation will seek to ascertain the extent to which Gossamer may have misled its shareholders.”

As investors reel from the impacts of the trial failure, the firm urges anyone who purchased Gossamer securities during the class period and suffered losses to submit their claims. It also calls upon any individuals who possess pertinent information regarding the trial to come forward.

Beyond the legal implications of this case, it also underscores a broader issue in the pharmaceutical industry, where the stakes are incredibly high and the trust between companies and investors must be carefully managed. The outcome of this litigation could set a significant precedent regarding investor rights in the realm of biopharmaceuticals and corporate governance. As it stands, Gossamer's narrative of potential multi-billion dollar opportunities has now turned into tumult as they navigate the repercussions of their failed trial and the ongoing investigation into their practices.

For those looking for more details about the ongoing lawsuit or those prepared to join the action, Hagens Berman has opened their lines for consultation and case inquiries, focusing on ensuring that justice ultimately prevails for the investors affected by this incident.

As the legal processes unfold, Gossamer's future remains uncertain, hinging upon the resolution of this case while investor confidence hangs in the balance. It serves as a cautionary tale for all stakeholders engaged in the high-stakes realm of biomedicine, where both innovation and accountability must go hand in hand.